selected scholarly activity
-
books
-
chapters
- Clinical Trials. Pediatric Oncology. 549-563. 2017
- Hodgkin Lymphoma. Pediatric Oncology. 119-133. 2017
- Acute Lymphoblastic Leukemia in Adults. 261-267. 2008
- Acute Myeloid Leukemia in Adults: Postremission Therapy. 278-286. 2008
- Acute Myeloid Leukemia in Adults: Remission Induction Therapy. 268-277. 2008
- Chronic Lymphocytic Leukemia. 294-299. 2008
- Chronic Myeloid Leukemia. 300-304. 2008
- Current Areas of Controversy in the Treatment of Patients with Newly Diagnosed Acute Promyelocytic Leukemia. 287-293. 2008
- Diffuse Large B‐Cell Lymphoma. 327-333. 2008
- Evidence‐Based Review of Therapies in Multiple Myeloma. 390-395. 2008
- Evidence‐Based Treatment of Burkitt Lymphoma in Adults. 311-316. 2008
- Follicular Lymphoma. 334-341. 2008
- Lymphoblastic Lymphoma. 342-346. 2008
- Lymphocyte Predominant Hodgkin Lymphoma. 372-377. 2008
- Management of Patients with Essential Thrombocythemia. 378-384. 2008
- Management of Patients with Peripheral T‐Cell Lymphoma. 352-364. 2008
- Management of Patients with Polycythemia Vera. 385-389. 2008
- Management of Waldenstrom's Macroglobulinemia. 396-401. 2008
- Mantle Cell Lymphoma. 347-351. 2008
- Primary Central Nervous System Lymphoma. 317-326. 2008
- Selected Management Issues of Patients with Hodgkin Lymphoma. 365-371. 2008
- Selected Management of Patients with Myelodysplastic Syndromes. 305-310. 2008
- The Role of Hematopoietic Growth Factors in Managing Patients with Hematologic Malignancies. 402-411. 2008
- Primary therapy for older patients with aggressive histology lymphoma. Clinical Respiratory Journal.
-
conferences
- Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial. Blood. 4076-4076. 2021
- Feasibility of a child life specialist program for oncology patients with minor children at home: Demand and implementation.. Journal of Clinical Oncology. 28-28. 2021
- Feasibility of a child life specialist program for oncology patients with minor children at home: Qualitative analysis.. Journal of Clinical Oncology. 30-30. 2021
- Long Term Survival After 2 Years Event Free Survival in Relapsed DLBCL After Autologous Transplantation in the Two Randomized Trials LY.12 and Coral. Bone Marrow Transplantation. 114-115. 2020
- Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).. Journal of Clinical Oncology. 2020
- The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).. Journal of Clinical Oncology. 2020
- Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral. Blood. 768-768. 2019
- The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement.. Journal of Clinical Oncology. e23142-e23142. 2019
- Limited stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): A subgroup analysis of the HD.6 clinical trial.. Journal of Clinical Oncology. 7535-7535. 2018
- Prospective linkage of clinical trial and administrative databases: Acceptability to patients and research ethics boards.. Journal of Clinical Oncology. e18692-e18692. 2018
- Comparison of Outcomes By Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD Alone; A Secondary Analysis of the Canadian Cancer Trial Group HD.6 Trial. Blood. 2017
- Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Blood. 2017
- Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial. Blood. 2017
- Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Blood. 690-690. 2016
- B06-C Improved Pain and Quality of Life as Early as Day 10 Following Radiotherapy for Painful Bone Metastases: A Secondary Analysis of the NCIC CTG SC.23 Randomized Trial. Journal of Pain and Symptom Management. e17-e18. 2016
- EFFECTS OF A STRUCTURED EXERCISE PROGRAM ON PHYSICAL ACTIVITY AND FITNESS IN COLON CANCER SURVIVORS: 1-YEAR FEASIBILITY RESULTS FROM THE CHALLENGE TRIAL AND STUDY UPDATE. Asia-Pacific Journal of Clinical Oncology. 79-80. 2016
- A Prospective Study Validating the EORTC QLQ–BM22 Bone Metastases Module in Patients With Painful Bone Metastases. International Journal of Radiation Oncology Biology Physics. E514-E514. 2016
- CONSTRUCTION OF A DECISION MODEL TO AID TREATMENT CHOICES FOR EARLY STAGE HODGKIN LYMPHOMA: BRINGING SURVIVORSHIP FORWARD. Haematologica. 16-17. 2016
- Minimal Clinically Important Differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL Modules in Patients With Bone Metastases. International Journal of Radiation Oncology Biology Physics. E512-E512. 2016
- A PROSPECTIVE STUDY VALIDATING THE EORTC QLQ-BM22 BONE METASTASES MODULE IN PATIENTS WITH PAINFUL BONE METASTASES. Radiotherapy and Oncology. S90-S91. 2016
- MINIMAL CLINICALLY IMPORTANT DIFFERENCES IN THE EORTC QLQ-BM22 AND EORTC QLQ-C15-PAL MODULES IN PATIENTS WITH BONE METASTASES. Radiotherapy and Oncology. S91-S91. 2016
- Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial.. Journal of Clinical Oncology. 3621-3621. 2016
- Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial.. Journal of Clinical Oncology. 648-648. 2016
- Dexamethasone Versus Placebo in the Prophylaxis of Radiation-induced Pain Flare Following Palliative Radiation Therapy for Bone Metastases: A Double-blind Randomized, Controlled, Superiority Trial. International Journal of Radiation Oncology Biology Physics. 1-1. 2016
- An Adjustable Markov Model to Project Life Expectancy (LE) for Early Stage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy. Blood. 2635-2635. 2015
- A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21).. Journal of Clinical Oncology. TPS3620-TPS3620. 2015
- Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12. Blood. 1712-1712. 2014
- Interpretation and Application of the International Myeloma Working Group (IMWG) Criteria: Proposal for Uniform Assessment and Reporting in Clinical Trials Based on the First Study Independent Response Adjudication Committee (IRAC) Experience. Blood. 3460-3460. 2014
- A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas.. Journal of Clinical Oncology. 8551-8551. 2014
- A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21).. Journal of Clinical Oncology. TPS3663-TPS3663. 2014
- A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial.. Journal of Clinical Oncology. 8591-8591. 2014
- Correlation between phase 2 clinical trial design and subsequent phase 3 outcome.. Journal of Clinical Oncology. 2549-2549. 2014
- The use of health-related quality of life outcomes in oncology practice: An international study.. Journal of Clinical Oncology. 6524-6524. 2014
- Outcomes of patients with peripheral T-cell lymphoma: a subset analysis of the NCIC Clinical Trials Group LY.12 Phase III clinical trial. British Journal of Haematology. 53-54. 2014
- A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12. Blood. 155-155. 2013
- Evaluation of the CONSORT extension recommendations for PRO reporting in clinical trials: an international survey of oncologists. Quality of Life Research. 2013
- Response and Quality of Life (QOL) Outcomes in a Randomized Trial of Single Versus Multiple Fractions (Fx) for Re-irradiation (RE-RT) of Painful Bone Metastases (PBM): NCIC CTG SC.20. International Journal of Radiation Oncology Biology Physics. S6-S6. 2013
- Use of PRO data from clinical trials to inform cancer care: an international perspective. Quality of Life Research. 2013
- A cost-minimization analysis of NCIC Clinical Trials Group LY.12: A phase III study of gemcitabine, clexamethasone, and cisplatin (GDP) compared to dexamethasone, cytarabine, and cisplatin (DHAP) for patients with relapsed or refractory aggressive histology non-Hodgkin's lymphoma. European Journal of Cancer. S326-S326. 2013
- Difficulties in meeting accrual and obtaining adequate follow up in palliative trials: Results from an intergroup randomized trial of single vs multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20. European Journal of Cancer. S269-S269. 2013
- A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). Journal of Clinical Oncology. 2013
- A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20.. Journal of Clinical Oncology. 2013
- Characteristics of clinical trials for adolescent and young adult (AYA) cancer patients (pts) in Ontario.. Journal of Clinical Oncology. 2013
- Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12. Blood. 745-745. 2012
- Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6. Blood. 271-272. 2011
- Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials. Blood. 237-237. 2011
- Randomized controlled trials (RCTs) in the era of molecular oncology: Methodology, biomarkers, and endpoints.. Journal of Clinical Oncology. 6049-6049. 2011
- Sponsor/research ethics boards (REB) communications about informed consent (IC) and time to local activation (LA): An NCIC CTG pilot study.. Journal of Clinical Oncology. 6131-6131. 2011
- Translation of evidence into funding policy: An overview of guidelines from the Cancer Care Ontario's Program in Evidence-Based Care (PEBC).. Journal of Clinical Oncology. e16513-e16513. 2011
- A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial. Blood. 23-23. 2010
- Clinically significant delayed cardiac morbidity following ABVD chemotherapy for Hodgkin lymphoma: A population-based study. Journal of Clinical Oncology. 2010
- Passive Transfer of Hepatitis B Core Antibody by Intravenous Immune Globulin-in Patients with Immune Thrombocytopenic Purpura. Blood. 955-955. 2009
- O4 Comorbidity, age and performance status are important predictors of outcome in older multiple myeloma patients treated with melphalan and corticosteroids: subgroup analysis from the National Cancer Institute of Canada MY7 trial. Critical Reviews in Oncology/Hematology. S15-S16. 2009
- Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial.. Blood. 954-955. 2008
- AGE AND SEX-SPECIFIC ESTIMATES OF CARDIOVASCULAR MORBIDITY FOLLOWING MODERN TREATMENT FOR HODGKIN'S LYMPHOMA: INCREASED RISK IN THE DOXORUBICIN ERA. Radiotherapy and Oncology. S35-S35. 2008
- Cardiovascular Morbidity following Modern Treatment for Hodgkin Lymphoma: Age- and Sex- Specific Estimates of Risk in the Doxorubicin Era. International Journal of Radiation Oncology Biology Physics. S122-S123. 2008
- Presentation of non-final results of randomized controlled trials (RCTs) at major oncology meetings. Journal of Clinical Oncology. 6550-6550. 2008
- Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: Toxicity data from the NCIC CTG MY.11 trial. Blood. 63A-63A. 2007
- Treatment decisions for young women with supra-diaphragmatic, limited-stage Hodgkin lymphoma: Exploration of options using a Markov decision analysis.. Blood. 116A-116A. 2007
- Treatment of solid malignant tumors with microwave balloon ablation catheters and localized chemotherapy. PIERS 2007 BEIJING: PROGRESS IN ELECTROMAGNETICS RESEARCH SYMPOSIUM, PTS I AND II, PROCEEDINGS. 481-483. 2007
- The Use of Erythropoietic Agents in Patients with Non-Myeloid Hematological Malignancies.. Blood. 3338-3338. 2006
- Maintenance therapy with thalidomide/prednisone post autologous stem-cell transplant for patients with multiple myeloma elevates D-dimer and possibly factor VIII levels.. Blood. 720A-720A. 2005
- Outcomes of previously untreated older patients with multiple myeloma (MM) over time: An analysis of 3 consecutive trials conducted by the NCICCTG, 1983-2003.. Blood. 722A-722A. 2005
- Relapse patterns and subsequent outcomes of patients treated on the NCICCTG HD.6 (ECOG JHD06) randomized trial evaluating ABVD alone in patients with limited stage Hodgkin lymphoma (HL).. Blood. 241A-241A. 2005
- Rituximab for the treatment of adults with ITP: A systematic review. Blood. 361A-361A. 2005
- A phase II study of ZD6474, a vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in patients with relapsed multiple myeloma (MM).. Blood. 944A-944A. 2004
- Results of a Multi-Center Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma Following Autologous Stem Cell Transplant.. Blood. 335-335. 2004
- The Effect of Prophylactic Administration of Myeloid Growth Factors Following Autologous Stem Cell Transplantation for Patients with Hematological Malignancies: A Systematic Review.. Blood. 2192-2192. 2004
- Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute of Canada Clinical Trials Group Study: MY.7.. Journal of Clinical Oncology. 560S-560S. 2004
- A phase II study of Bortezomib in patients with mantle cell lymphoma. Blood. 902A-903A. 2003
- A randomized phase III comparison of single-modality ABVD with a strategy that includes radiation therapy in patients with early-stage Hodgkin's disease: The HD-6 trial of the National Cancer Institute of Canada Clinical Trials Group (Eastern Cooperative Oncology Group Trial JHD06).. Blood. 26A-26A. 2003
- Rituximab for indolent lymphoma: An analysis of outcomes in a large population-wide study.. Blood. 505B-506B. 2003
- The ability to harvest increased numbers of peripheral blood progenitor cells is a predictor of improved overall survival in patients with multiple myeloma treated by autologous hematopoietic stem cell transplantation. Blood. 983A-983A. 2003
- Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013. Leukemia and Lymphoma. 39-48. 2003
- Gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy for relapsed or refractory Hodgkin's disease (HD): A National Cancer Institute of Canada Clinical Trials Group Study.. Blood. 570A-570A. 2002
- Gemcitabine, dexamethasone, cisplatin for relapsed or refractory non-Hodgkin's lymphoma (NHL): A National Cancer Institute of Canada Clinical Trials Group study.. Blood. 778A-778A. 2002
- Prophylactic growth factor use in older patients with previously untreated acute myeloid leukemia: A published data meta-analysis.. Blood. 563A-563A. 2002
- Rituximab in lymphoma: A review of a province-wide initiative after one year.. Blood. 432A-432A. 2001
- A strategy of peripheral blood stem cell transplantation is cost-effective compared to melphalan and prednisone in younger patients with multiple myeloma.. Blood. 846A-846A. 2000
- Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: Are trial results generalized to other patient populations?. Blood. 132A-132A. 2000
- Patients with multiple myeloma transplanted with increased numbers of PBPC demonstrate early recovery of total lymphocytes.. Blood. 335B-335B. 2000
- Phase I-II trial of VACOP-B plus filgrastim (G-CSF) support for HIV-related non-Hodgkins lymphoma (NHL).. Blood. 138A-138A. 2000
- Seropositive symmetrical inflammatory polyarthritis appearing after treatment with fludarabine in a patient with non-Hodgkin's lymphoma.. Blood. 241B-241B. 2000
- A randomized trial comparing plasma removal to two types of pre-storage leukoreduction to prevent reactions to platelets.. Blood. 376A-376A. 1999
- Phase II study of topotecan plus etoposide in patients with aggressive histology non-Hodgkin's lymphoma (NHL).. Blood. 526A-526A. 1999
- The preferences of traditional quality of life domains are similar in older versus younger patients with non-Hodgkin's lymphoma.. Blood. 185A-185A. 1999
- A randomized trial comparing plasma removal to two types of pre-storage leukoreduction to prevent reactions to platelets. Transfusion. 96S-97S. 1999
- Acute reactions to platelets: A new classification and interobserver reliability studies.. Transfusion. 40S-40S. 1998
- Face validity of a new classification for platelet reactions.. Transfusion. 43S-43S. 1998
- The development of a practice guideline for treating newly diagnosed patients with chronic myelocytic leukemia. Leukemia and Lymphoma. 24-26. 1998
- A comparison of two interventions to prevent platelet reactions.. Transfusion. S185-S185. 1996
- Critical appraisal of interferon therapy for chronic myeloid leukemia.. Blood. 3201-3201. 1995
- DAY-6 BONE-MARROW (D6BM) PREDICTS FOR COMPLETE REMISSION (CR) IN ADULTS WITH ACUTE MYELOID-LEUKEMIA (AML). Blood. A303-A303. 1994
- EFFICACY OF ANTI-D TO IMPROVE PLATELET TRANSFUSION RESPONSE - A RANDOMIZED TRIAL. Blood. A403-A403. 1993
-
journal articles
- Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trial. Leukemia and Lymphoma. 65:1-8. 2024
- Biopsychosocial Associates of Psychological Distress and Post-Traumatic Growth among Canadian Cancer Patients during the COVID-19 Pandemic.. Current Oncology. 31:5354-5366. 2024
- Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy. BMC Cancer. 24:984. 2024
- Patient and Provider Attitudes and Preferences Regarding Early Palliative Care Delivery for Patients with Advanced Gastrointestinal Cancers: A Prospective Survey. Current Oncology. 31:3329-3341. 2024
- Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. The Lancet. 403:2405-2415. 2024
- Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. The Lancet. 403:2416-2425. 2024
- Integration of child life into adult oncology: A mixed‐methods feasibility study. Psycho-Oncology. 33:e6365. 2024
- Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6. Supportive Care in Cancer. 31:256. 2023
- Post-discharge after surgery Virtual Care with Remote Automated Monitoring-1 (PVC-RAM-1) technology versus standard care: randomised controlled trial. The BMJ. 374:n2209-n2209. 2021
- Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Current Oncology. 28:1256-1261. 2021
- A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data. Current Oncology. 28:1153-1160. 2021
- Post Discharge after Surgery Virtual Care with Remote Automated Monitoring Technology (PVC-RAM): protocol for a randomized controlled trial. CMAJ open. 9:E142-E148. 2021
- Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma. JAMA Oncology. 6:989-989. 2020
- Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).. Journal of Clinical Oncology. 38:12068-12068. 2020
- The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).. Journal of Clinical Oncology. 38:e20019-e20019. 2020
- The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. Blood Advances. 4:2011-2017. 2020
- Early‐stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long‐term patient outcomes. British Journal of Haematology. 182:212-221. 2018
- Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases. Quality of Life Research. 27:1089-1098. 2018
- Patient Reported Outcomes After Radiation Therapy for Bone Metastases as a Function of Age: A Secondary Analysis of the NCIC CTG SC—Twenty-Three Randomized Trial. American Journal of Hospice and Palliative Medicine. 35:718-723. 2018
- Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial. Radiotherapy and Oncology. 126:541-546. 2018
- Magnolol inhibits venous remodeling in mice. Scientific Reports. 7:17820. 2017
- Gender differences in pain and patient reported outcomes: a secondary analysis of the NCIC CTG SC. 23 randomized trial. Annals of Palliative Medicine. 6:S185-S194. 2017
- Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study. Leukemia and Lymphoma. 58:2319-2327. 2017
- Reply to J.A. Vargo et al, H.J.A. Adams et al, E. Hindié et al, and S. Kothari et al. Journal of Clinical Oncology. 35:2854-2855. 2017
- Effect of Radiotherapy on Painful Bone Metastases. JAMA Oncology. 3:953-953. 2017
- Limited-Stage Hodgkin Lymphoma: Clarifying Uncertainty. Journal of Clinical Oncology. 35:1760-1763. 2017
- Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*. Leukemia and Lymphoma. 58:64-69. 2017
- Classification of painful bone metastases as mild, moderate, or severe using both EORTC QLQ-C15-PAL and EORTC QLQ-BM22. Supportive Care in Cancer. 24:4871-4878. 2016
- Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy. Quality of Life Research. 25:2535-2541. 2016
- 249: A Prospective Study Validating the EORTC QLQ–BM22 Bone Metastases Module in Patients With Painful Bone Metastases. Radiotherapy and Oncology. 120:S90-S91. 2016
- 250: Minimal Clinically Important Differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-Pal Modules in Patients with Bone Metastases. Radiotherapy and Oncology. 120:S91-S91. 2016
- A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma. Blood. 128:732-735. 2016
- Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalatedPlus Four Cycles of BEACOPPbaselinein Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical Oncology. 34:2028-2036. 2016
- Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial. Cancer Epidemiology, Biomarkers and Prevention. 25:969-977. 2016
- A prospective study validating the EORTC QLQ-BM22 bone metastases module in patients with painful bone metastases undergoing palliative radiotherapy. Radiotherapy and Oncology. 119:208-212. 2016
- Accrual of Adolescents and Young Adults with Cancer to Clinical Trials. Current Oncology. 23:81-85. 2016
- Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life. Supportive Care in Cancer. 24:1617-1623. 2016
- Predictive model for survival in patients having repeat radiation treatment for painful bone metastases. Radiotherapy and Oncology. 118:547-551. 2016
- Varicose Remodeling of Veins Is Suppressed by 3‐Hydroxy‐3‐Methylglutaryl Coenzyme A Reductase Inhibitors. Journal of the American Heart Association. 5:e002405. 2016
- Prophylactic dexamethasone for radiation-induced bone-pain flare – Authors' reply. The Lancet Oncology. 17:e40-e41. 2016
- Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. Clinical Lymphoma, Myeloma and Leukemia. 16:18-28.e4. 2016
- Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. European Journal of Cancer. 51:2501-2507. 2015
- Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. The Lancet Oncology. 16:1463-1472. 2015
- Impact of the addition of chemotherapy to radiotherapy for oropharyngeal cancer in 2003–2004: Population‐based study from the Province of Ontario, Canada. Head and Neck. 37:1461-1469. 2015
- Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood. 126:733-738. 2015
- Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12. Journal of the National Cancer Institute. 107:djv106. 2015
- Integrating health-related quality of life findings from randomized clinical trials into practice: an international study of oncologists’ perspectives. Quality of Life Research. 24:1317-1325. 2015
- Abstract 304: Varicose Vein Development in Mice Is Blocked by Ator- and Rosuvastatin. Arteriosclerosis, Thrombosis and Vascular Biology. 35. 2015
- Effect of re-irradiation for painful bone metastases on urinary markers of osteoclast activity (NCIC CTG SC.20U). Radiotherapy and Oncology. 115:141-148. 2015
-
Thalidomide‐prednisone maintenance following autologous stem cell transplant for
M ultipleM yeloma: effect on thrombin generation and procoagulant markers inNCIC CTG MY .10. British Journal of Haematology. 168:511-517. 2015 - Impact of Reirradiation of Painful Osseous Metastases on Quality of Life and Function: A Secondary Analysis of the NCIC CTG SC.20 Randomized Trial. Journal of Clinical Oncology. 32:3867-3873. 2014
- Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. Journal of Clinical Oncology. 32:3490-3496. 2014
- Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors. Current Colorectal Cancer Reports. 10:321-328. 2014
- Bortezomib protects from varicose‐like venous remodeling. The FASEB Journal. 28:3518-3527. 2014
- Limited-Stage Hodgkin Lymphoma: Managing Uncertainty. Journal of Clinical Oncology. 32:1180-1182. 2014
- Balancing Risks and Benefits of Therapy for Patients with Favorable-Risk Limited-Stage Hodgkin Lymphoma. Hematology/Oncology Clinics of North America. 28:49-63. 2014
- Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. The Lancet Oncology. 15:164-171. 2014
- An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Annals of Oncology. 24:3065-3069. 2013
- CLINICAL USE OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM CANCER CLINICAL TRIALS: PRELIMINARY RESULTS FROM A SURVEY OF ONCOLOGISTS. Journal of Epidemiology and Community Health. 67:e2.17-e2. 2013
- Surrogacy of Financial Conflicts of Interest. Journal of Clinical Oncology. 31:2645-2647. 2013
- Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute-Sponsored Trials. Journal of the National Cancer Institute. 105:954-959. 2013
- A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21).. Journal of Clinical Oncology. 31:TPS3647-TPS3647. 2013
- A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20.. Journal of Clinical Oncology. 31:9502-9502. 2013
- Characteristics of clinical trials for adolescent and young adult (AYA) cancer patients (pts) in Ontario.. Journal of Clinical Oncology. 31:e17525-e17525. 2013
- EBV DNA: a Hodgkin lymphoma biomarker?. Blood. 121:3541-3542. 2013
- Radiation in early-stage Hodgkin lymphoma.. Clinical Advances in Hematology and Oncology. 11:162-189. 2013
- A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood. 121:1517-1523. 2013
- Alignment of Practice Guidelines with Targeted-therapy Drug Funding Policies in Ontario. Current Oncology. 20:21-33. 2013
- Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial. Clinical Lymphoma, Myeloma and Leukemia. 13:19-24. 2013
- Treatment Success in Cancer: Industry Compared to Publicly Sponsored Randomized Controlled Trials. PLoS ONE. 8:e58711-e58711. 2013
- Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. Blood. 120:4488-4495. 2012
- Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone. Blood. 120:548-548. 2012
- Hepatitis B, Rituximab, Screening, and Prophylaxis: Effectiveness and Cost Effectiveness. Journal of Clinical Oncology. 30:3155-3157. 2012
- Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. Annals of Oncology. 23:1646-1651. 2012
- Durch die Augen von Laplace: Die Rolle der Wandspannung bei Varikosis. Phlebologie. 41:61-67. 2012
- A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 119:1356-1362. 2012
- ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma. New England Journal of Medicine. 366:399-408. 2012
- Evolution of Clinical Trials Registries. Journal of Clinical Oncology. 30:131-133. 2012
- Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.. Hematology. American Society of Hematology. Education Program. 2012:313-321. 2012
- Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group. Journal of the Canadian Urological Association. 5:379-381. 2011
- Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6. Blood. 118:590-590. 2011
- Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials. Blood. 118:508-508. 2011
- Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The Lancet. 378:771-784. 2011
- Active therapy and models of care for adolescents and young adults with cancer. Cancer. 117:2316-2322. 2011
- Phase II/III Study of Intraperitoneal Chemotherapy after Neoadjuvant Chemotherapy for Ovarian Cancer: NCIC CTG OV.21. Current Oncology. 18:84-90. 2011
- Randomised controlled trials in oncology closed early for benefit: Trends in methodology, results, and interpretation. European Journal of Cancer. 47:854-863. 2011
- Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia. Transfusion. 50:2577-2581. 2010
- A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial. Blood. 116:39-39. 2010
- A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood. 116:2237-2240. 2010
- Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Review of Pharmacoeconomics and Outcomes Research. 10:119-128. 2010
- Generalizing the Results of Cancer Clinical Trials. Journal of Clinical Oncology. 28:187-189. 2010
- The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline. Transfusion Medicine Reviews. 24:S7-S27. 2010
- Passive Transfer of Hepatitis B Core Antibody by Intravenous Immune Globulin in Patients with Immune Thrombocytopenic Purpura.. Blood. 114:2418-2418. 2009
- Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials. Journal of Clinical Oncology. 27:5109-5114. 2009
- I-Tositumomab in lymphoma.. Current Oncology. 16:32-47. 2009
- Presentation of Nonfinal Results of Randomized Controlled Trials at Major Oncology Meetings. Journal of Clinical Oncology. 27:3938-3944. 2009
- Stopping a trial early in oncology: for patients or for industry?. Annals of Oncology. 20:395-396. 2009
- 131I–Tositumomab in Lymphoma. Current Oncology. 16:32-47. 2009
- 131I-tositumomab in lymphoma. Current Oncology. 16:32-47. 2009
- The Colon Health and Life-Long Exercise Change (CHALLENGE) trial (CO.21). Current Oncology. 15:279-285. 2008
- The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group. Current Oncology. 15:262-270. 2008
- The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review. Annals of Hematology. 87:961-973. 2008
- Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial. Blood. 112:2767-2767. 2008
- The Use of IVIG for Solid Organ Transplantation: An Evidence Based Practice Guideline. Blood. 112:4666-4666. 2008
- Health-Related Quality of Life for Extremely Low Birth Weight Adolescents in Canada, Germany, and the Netherlands. Pediatrics. 122:556-561. 2008
- A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treatment Reviews. 34:442-452. 2008
- Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group. Current Oncology. 15:179-184. 2008
- Stopping Trials for Benefit Can (Sometimes) Benefit Patients. Journal of Clinical Oncology. 26:2787-2788. 2008
- Defining the optimal treatment strategy for localized prostate cancer patients: A survey of ongoing studies at the National Cancer Institute of Canadia Clinical Trials Group. Current Oncology. 15:14-19. 2008
- The Colon Health and Life-Long Exercise Change trial: A randomized trial of the National Cancer Institute of Canada Clinical Trials Group. Current Oncology. 15:8-16. 2008
- Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.. Blood. 110:189-189. 2007
- Biomarkers and the Design of Clinical Trials in Cancer. Biomarkers in Medicine. 1:387-397. 2007
- Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Annals of Oncology. 18:1680-1684. 2007
- Phase II Testing of Sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185. Current Oncology. 14:154-161. 2007
- Tetrahydro-1,8-naphthyridinol Analogues of α-Tocopherol as Antioxidants in Lipid Membranes and Low-Density Lipoproteins. Journal of the American Chemical Society. 129:10211-10219. 2007
- Alemtuzumab in Chronic Lymphocytic Leukemia. Current Oncology. 14:96-109. 2007
- Addition of Lenalidomide to Melphalan in the Treatment of Newly Diagnosed Multiple Myeloma: The National Cancer Institute of Canada Clinical Trials Group MY.11 Trial. Current Oncology. 14:61-65. 2007
- Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions. Transfusion Medicine Reviews. 21:S9-S56. 2007
- Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treatment Reviews. 33:161-176. 2007
- Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura. ACP journal club. 146:25-25. 2007
- A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. British Journal of Haematology. 136:203-211. 2007
- Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria. Leukemia and Lymphoma. 48:513-520. 2007
- Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Annals of Oncology. 17:1749-1760. 2006
- A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145. Investigational New Drugs. 24:529-535. 2006
- Cheung MC, Haynes AE, Stevens A, Meyer RM, Imrie K, et al. Yttrium 90 ibritumomab tiuxetan in lymphoma. Leuk Lymphoma 2006;47:967 – 977. Leukemia and Lymphoma. 47:1719-1720. 2006
- The Management of Patients with Limited-Stage Classical Hodgkin Lymphoma. Hematology. American Society of Hematology. Education Program. 2006:253-258. 2006
- Yttrium 90 ibritumomab tiuxetan in lymphoma. Leukemia and Lymphoma. 47:967-977. 2006
- In Reply:. Journal of Clinical Oncology. 23:8915-8916. 2005
- Maintenance Therapy with Thalidomide/Prednisone Post Autologous Stem-Cell Transplant for Patients with Multiple Myeloma Elevates D-Dimer and Possibly Factor VIII Levels.. Blood. 106:2561-2561. 2005
- Outcomes of Previously Untreated Older Patients with Multiple Myeloma (MM) over Time: An Analysis of 3 Consecutive Trials Conducted by the NCIC CTG, 1983–2003.. Blood. 106:2568-2568. 2005
- Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).. Blood. 106:817-817. 2005
- Rituximab for the Treatment of Adults with ITP: A Systematic Review.. Blood. 106:1241-1241. 2005
- Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin’s Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 23:4634-4642. 2005
- Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma?. European Journal of Haematology. 75:115-120. 2005
- Autologous peripheral blood progenitor cells are a potential source of parvovirus B19 infection. Transfusion. 45:394-398. 2005
- Role of bisphosphonates in the management of skeletal complications in patients with multiple myeloma. Current Oncology. 12:3-17. 2005
- Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant. Clinical Cancer Research. 10:8170-8176. 2004
- An Evaluation of Age-related Differences in Quality of Life Preferences in Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma. 45:2471-2476. 2004
- A Phase II Study of ZD6474, a Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed Multiple Myeloma (MM).. Blood. 104:3464-3464. 2004
- Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma. Cancer. 101:1835-1842. 2004
- Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute Of Canada Clinical Trials Group Study: MY.7. Journal of Clinical Oncology. 22:6510-6510. 2004
- Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute Of Canada Clinical Trials Group Study: MY.7. Journal of Clinical Oncology. 22:6510-6510. 2004
- Hodgkin’s Lymphoma: Evolving Concepts with Implications for Practice. Hematology. American Society of Hematology. Education Program. 2004:184-202. 2004
- Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Annals of Oncology. 14:1762-1767. 2003
- Routine Tandem Transplantation for Patients with Myeloma. ACP journal club. 139:w-55. 2003
- Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 21:1740-1745. 2003
- Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma. Leukemia and Lymphoma. 44:29-37. 2003
- Randomized Phase III Study of Fludarabine Phosphate Versus Cyclophosphamide, Vincristine, and Prednisone in Patients With Recurrent Low-Grade Non-Hodgkin’s Lymphoma Previously Treated With an Alkylating Agent or Alkylator-Containing Regimen. Journal of Clinical Oncology. 20:4649-4654. 2002
- A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets. Transfusion. 42:556-566. 2002
- The Role of High-Dose Chemotherapy and Stem-Cell Transplantation in Patients with Multiple Myeloma: A Practice Guideline of the Cancer Care Ontario Practice Guidelines Initiative. ACP journal club. 136:619-619. 2002
- Chemotherapy for Older Patients with Newly Diagnosed, Advanced-Stage, Aggressive-Histology Non-Hodgkin Lymphoma. ACP journal club. 136:144-144. 2002
- Phase II Study of Sequential Topotecan and Etoposide in Patients with Intermediate Grade Non-Hodgkin's Lymphoma: A National Cancer Institute of Canada Clinical Trials Group Study. Leukemia and Lymphoma. 43:1581-1587. 2002
- Understanding outcome measures. Growth Hormone and IGF Research. 2:172-176. 2001
- Treatment Strategies in Elderly Patients with Aggressive Histology Lymphoma. Annals of Hematology. 80:B86-B88. 2001
- CD34‐positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. American Journal of Hematology. 67:34-41. 2001
- Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: are trial results generalized to other patient populations?. Blood. 96. 2000
- Patients with multiple myeloma transplanted with increased numbers of pbpc demonstrate early recovery of total lymphocytes. Blood. 96. 2000
- Phase i-n trial of vacop-b + filgrastim (g-csf) support for hiv-related non-hodgkins lymphoma (nhl). Blood. 96. 2000
- A Comparison of Elderly Patients with Aggressive Histology Lymphoma who Were Entered or Not Entered on to a Randomized Phase II Trial. Leukemia and Lymphoma. 38:327-334. 2000
- Drug therapy for chronic myeloid leukaemia. Current Oncology. 7:229-241. 2000
- Seropositive symmetrical inflammatory polyarthritis appearing after treatment with fludarabine in a patient with non-hodgkin's lymphoma. Blood. 96. 2000
- A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion. 39:231-238. 1999
- The role of fludarabine in intermediate- and high-risk chronic lymphocytic leukaemia. Current Oncology. 6:90-102. 1999
- Use of rituximab in the treatment of lymphoma: An evidence summary. Current Oncology. 6:228-235. 1999
- A Phase I Trial of Standard and Cyclophosphamide Dose-Escalated CHOP with Granulocyte Colony Stimulating Factor in Elderly Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma. 30:591-600. 1998
- The Development of a Practice Guideline for Treating Newly Diagnosed Patients with Chronic Myelocytic Leukemia. Leukemia and Lymphoma. 30:24-26. 1998
- Treatment of Advanced Hodgkin's Disease With Chemotherapy—Comparison of MOPP/ABV Hybrid Regimen With Alternating Courses of MOPP and ABVD. Journal of Clinical Oncology. 15:2762-2762. 1997
- Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.. Journal of Clinical Oncology. 15:1638-1645. 1997
- CD2+, CD3‐, CD56/NCAM+ malignant lymphoma with TCRβ gene rearrangement: A case report. American Journal of Hematology. 50:209-214. 1995
- Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 13:2386-2393. 1995
- Implications of using a prognostic index to select therapy for patients with aggressive histology lymphoma.. The Canadian journal of oncology. 5:344-354. 1995
- The use of anti‐D to improve post‐transfusion platelet response: a randomized trial. British Journal of Haematology. 89:163-168. 1995
- Relation between platinum-DNA adducts and complete remission in adult acute nonlymphocytic leukemia. Leukemia Research. 18:659-664. 1994
- Escalated as Compared with Standard Doses of Doxorubicin in BACOP Therapy for Patients with Non-Hodgkin's Lymphoma. New England Journal of Medicine. 329:1770-1776. 1993
- A pilot study of carboplatin augmentation therapy for patients with poor risk acute non-lymphocytic leukemia. Leukemia Research. 16:159-163. 1992
- Dose intensity and lymphoma.. Journal of Clinical Oncology. 9:1511-1511. 1991
- Rotational step-cut osteotomy for treatment of metacarpal and phalangeal malunion. Journal of Hand Surgery-American Volume. 16:551-555. 1991
- The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 9:339-347. 1991
- Diagnosis of iron-deficiency anemia in the elderly. American Journal of Medicine. 88:205-209. 1990
- Platelet specific alloantigens on the platelet glycoprotein Ia/IIa complex. British Journal of Haematology. 72:534-538. 1989
- Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study. British Journal of Haematology. 71:493-497. 1989
- A prospective comparison of four techniques for measuring platelet‐associated IgG. British Journal of Haematology. 71:97-105. 1989
- Getting Started: Reading Techniques That Work From the Very First Day. Foreign Language Annals. 21:423-431. 1988
- Prognostic implications of basophil differentiation in chronic myeloid leukemia. American Journal of Hematology. 27:110-114. 1988
- Classifying acute leukemia by immunophenotyping: a combined FAB- immunologic classification of AML. Blood. 68:1355-1362. 1986
- Multiple myeloma.. Canadian Family Physician. 31:1231-1237. 1985
- Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective. Journal of the Canadian Urological Association. 5:379-379.
-
preprints